Pre-made Regavirumab benchmark antibody (Whole mAb, anti-HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Anti-HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] therapeutic antibody (Pre-made Regavirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-970-1mg	1mg	3090
GMP-Bios-INN-970-10mg	10mg	Inquiry
GMP-Bios-INN-970-100mg	100mg	Inquiry
GMP-Bios-INN-970-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Regavirumab Biosimilar, Whole Mab: Anti-Hcmv (Human Cytomegalovirus) Envelope Glycoprotein B (Gb) [Human Betaherpesvirus 5] therapeutic antibody
INN Name	Regavirumab
Target	HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5]
Format	Whole mAb
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Teijin Ltd. (Tokyo Japan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	Human hybridoma